Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O; ANRS VAC18 trial group. Salmon-Céron D, et al. Among authors: launay o. AIDS. 2010 Sep 10;24(14):2211-23. doi: 10.1097/QAD.0b013e32833ce566. AIDS. 2010. PMID: 20625264 Clinical Trial.
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Yéni P; Agence Nationale de Recherches sur le SIDA (ANRS) 081 Study Group. Launay O, et al. Clin Infect Dis. 2002 Nov 1;35(9):1096-105. doi: 10.1086/342694. Epub 2002 Oct 15. Clin Infect Dis. 2002. PMID: 12384844 Clinical Trial.
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
Morand-Joubert L, Marcellin F, Launay O, Guiramand-Hugon S, Gérard L, Yeni P, Aboulker JP; Agence Nationale de Recherches sur le SIDA 081 Study Group. Morand-Joubert L, et al. Among authors: launay o. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):268-76. J Acquir Immune Defic Syndr. 2005. PMID: 15735443 Clinical Trial.
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group. Allavena C, et al. Among authors: launay o. J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6. doi: 10.1097/01.qai.0000165914.42827.bb. J Acquir Immune Defic Syndr. 2005. PMID: 15980689 Clinical Trial.
Feasibility of azithromycin prophylaxis during a pertussis outbreak among healthcare workers in a university hospital in Paris.
Giugliani C, Vidal-Trecan G, Traore S, Blanchard H, Spiridon G, Rollot F, Launay O, Gorodestski M, Marande JL, Vinsonneau C, Guillevin L, Salmon-Ceron D. Giugliani C, et al. Among authors: launay o. Infect Control Hosp Epidemiol. 2006 Jun;27(6):626-9. doi: 10.1086/505102. Epub 2006 May 31. Infect Control Hosp Epidemiol. 2006. PMID: 16755485
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figuereido S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG; ANRS VAC16 Study Group. Launay O, et al. PLoS One. 2007 Aug 22;2(8):e725. doi: 10.1371/journal.pone.0000725. PLoS One. 2007. PMID: 17712402 Free PMC article. Clinical Trial.
501 results